Open an account

Cullinan Therapeutics

CGEM · NASDAQ

$14.83+$0.85 (+6.08%)TodayMarket closed ·
Prev close $13.98

About CGEM

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 109 full-time employees. The company went IPO on 2021-01-08. The company has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.

Employees
109
Headquarters
Cambridge, Massachusetts
Listed
Jan 8, 2021
Sector
Health Care
Industry
Biotechnology
Website
cullinantherapeutics.com

CGEM key statistics

Market cap
899.68M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.17M
Volume
694.03K
Open price
$13.88
High today
$14.92
Low today
$13.85
52 Week high
$23.19
52 Week low
$6.73

Cullinan Therapeutics (CGEM) at a glance

As of Oct 20, 2026, Cullinan Therapeutics (CGEM) shares are priced at $14.83, giving the company a market cap of 899.68M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $13.85 and $14.92. The current price is 7.1% above the day's low and 0.6% below its high.

Volume so far is 694.03K shares, below the average of 1.17M shares a day.

Over the past year Cullinan Therapeutics has ranged from $6.73 to $23.19, and now sits 49% of the way up that range.

Cullinan Therapeutics met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.81 per share against an estimate of -$0.826.

The average analyst price target is $37.82, 155.1% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 14 analystsAvg $37.82
Low
$27.27
Now
$14.83
High
$55.65

CGEM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 10.3% on average.

  1. Q3 FY24: reported -$0.69 per share against an estimate of -$0.8221
  2. Q4 FY24: reported -$0.73 per share against an estimate of -$0.7729
  3. Q1 FY25: reported -$0.74 per share against an estimate of -$0.8173
  4. Q2 FY25: reported -$1.07 per share against an estimate of -$0.8497
  5. Q3 FY25: reported -$0.77 per share against an estimate of -$0.9764
  6. Q4 FY25: reported -$0.77 per share against an estimate of -$0.8256
  7. Q1 FY26: reported -$0.75 per share against an estimate of -$0.8453
  8. Q2 FY26: reported -$0.81 per share against an estimate of -$0.826

CGEM news

  • Press releaseBusiness Wire

    Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases

  • Press releaseBusiness Wire

    Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

  • Press releaseBusiness Wire

    Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

  • Vandana Singh

    Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Press releaseBusiness Wire

    Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

  • Press releaseGlobe Newswire

    Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

  • Press releaseGlobe Newswire

    Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Similar companies

Companies in the same industry as Cullinan Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.